

Japan Plasma-Derived Therapeutics Market - 2024-2033

<https://marketpublishers.com/r/JAF09470E335EN.html>

Date: February 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: JAF09470E335EN

Abstracts

The Japan Plasma-Derived Therapeutics Market was valued at US\$ 1.95 Billion in 2024 and is anticipated to reach US\$ 3.53 Billion by 2033, at a CAGR of 0.068 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Japan Plasma-Derived Therapeutics Market.

This report delivers a comprehensive overview of the Japan Plasma-Derived Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Plasma-Derived Therapeutics Market. The Japan Plasma-Derived Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Japan Plasma-Derived Therapeutics Market Scope:

By Product Type

Immunoglobulins

Coagulation Factors

Albumin

Protease Inhibitors

Others

By Application

Multiple Sclerosis

Neuropathies

Primary Immunodeficiency Disorders

Hemophilia

Autoimmune Diseases

Critical Care & Trauma

Others

By End User

Hospitals

Specialty Clinics

Homecare Settings

Ambulatory Surgical Centers

Others

By Source of Plasma

Whole Blood Plasma

Apheresis Plasma

Recovered Plasma

By Route of Administration

Intravenous

Subcutaneous

Intramuscular

Key Players

Takeda Pharmaceutical Company Limited

Japan Blood Products Organization

CSL Behring

Grifols

Octapharma A G

Kedrion Biopharma Inc

Baxter International

KM Biologics

Biotest AG

LFB Group

Major Highlights

This report delivers a comprehensive overview of the Japan Plasma-Derived Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Japan Plasma-Derived Therapeutics Market. The Japan Plasma-Derived Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned

to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Improved Diagnostic Capabilities & Rare Disease Screening
 - 3.1.1.2. Technological Advancements in Plasma Fractionation
 - 3.1.1.3. Growing Demand for Critical Care & Emergency Preparedness
 - 3.1.2. Restraints
 - 3.1.2.1. Limited Domestic Plasma Supply
 - 3.1.2.2. Strict Regulatory Requirements in Japan
 - 3.1.3. Opportunity
 - 3.1.3.1. Increasing Diagnosis of Rare & Immune Disorders
 - 3.1.3.2. Strategic Partnerships & Technology Upgrades
 - 3.1.3.3. Advancements in High-Purity & Specialty Plasma Proteins
 - 3.1.4. Trends
 - 3.1.4.1. Strategic Capacity Expansion by Domestic Players
 - 3.1.4.2. Hospital-Centric Procurement Dominance
 - 3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

- 4.1. Porter's Five Force Analysis – Japan Plasma-Derived Therapeutics Market
- 4.2. Geopolitical & Supply Chain Exposure
- 4.3. Social & Patient-Centric Factors
- 4.4. Economic Factors
- 4.5. Pricing Analysis
- 4.6. Regulatory Analysis
- 4.7. Go-To-Market (GTM) Strategy
- 4.8. Innovation & R&D Trends
- 4.9. Sustainability and ESG Analysis
- 4.10. Plasma-Derived Therapeutics Market Participants
- 4.11. Buyer Decision Criteria & Adoption Drivers
- 4.12. DMI Opinion – Strategic Outlook for the Japan Plasma-Derived Therapeutics Market

5. BY PRODUCT TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 5.1.2. Market Attractiveness Index, By Product Type
- 5.2. Immunoglobulins
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Coagulation Factors
- 5.4. Albumin
- 5.5. Protease Inhibitors
- 5.6. Others

6. BY APPLICATION

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 6.1.2. Market Attractiveness Index, By Application
- 6.2. Multiple Sclerosis
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Neuropathies

- 6.4. Primary Immunodeficiency Disorders
- 6.5. Hemophilia
- 6.6. Autoimmune Diseases
- 6.7. Critical Care & Trauma
- 6.8. Others

7. BY END USER

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
 - 7.1.2. Market Attractiveness Index, By End User
- 7.2. Hospitals
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Specialty Clinics
- 7.4. Homecare Settings
- 7.5. Ambulatory Surgical Centers
- 7.6. Others

8. BY SOURCE OF PLASMA

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source of Plasma
 - 8.1.2. Market Attractiveness Index, By Source of Plasma
- 8.2. Whole Blood Plasma
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Apheresis Plasma
- 8.4. Recovered Plasma

9. BY ROUTE OF ADMINISTRATION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Intravenous
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Subcutaneous

9.4. Intramuscular

10. COMPETITIVE LANDSCAPE ANALYSIS

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 10.4. Partner Identification Analysis
- 10.5. Investment & Funding Landscape
- 10.6. Strategic Alliances & Innovation Pipelines

11. COMPANY PROFILES

- 11.1. Takeda Pharmaceutical Company Limited
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio
 - 11.1.3. Revenue Analysis
 - 11.1.4. Pricing Analysis
 - 11.1.5. SWOT Analysis
 - 11.1.6. Recent Developments
 - 11.1.6.1. Major Deals
 - 11.1.6.2. M&A
 - 11.1.6.3. Collaboration
 - 11.1.6.4. Acquisition
 - 11.1.6.5. Joint Ventures
 - 11.1.6.6. Innovations
 - 11.1.7. Recent News
 - 11.1.7.1. Events
 - 11.1.7.2. Conferences
 - 11.1.7.3. Symposiums
 - 11.1.7.4. Webinars
- 11.2. Japan Blood Products Organization
- 11.3. CSL Behring
- 11.4. Grifols
- 11.5. Octapharma A G
- 11.6. Kedrion Biopharma Inc
- 11.7. Baxter International
- 11.8. KM Biologics
- 11.9. Biotest AG

11.10. LFB Group (LIST NOT EXHAUSTIVE)

12. JAPAN PLASMA-DERIVED THERAPEUTICS MARKET – RESEARCH METHODOLOGY

12.1. Research Data

12.1.1. Secondary Data

12.1.2. Primary Data

12.1.3. CAGR Analysis

12.2. Market Size Estimation Methodology

12.2.1. Bottom-Up Approach

12.2.2. Top-Down Approach

12.3. Market Breakdown & Data Triangulation

12.4. Research Assumptions

12.5. Limitations

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Japan Plasma-Derived Therapeutics Market - 2024-2033

Product link: <https://marketpublishers.com/r/JAF09470E335EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JAF09470E335EN.html>